Abstract
Background:
Polidocanol is a liquid surfactant having endothelial cell lytic properties. In the form of a controlled, dispensed microfoam it is administered endovenously as a sclerosing agent in the treatment of varicose veins.
Objective:
This review summarizes efficacy of polidocanol endovenous microfoam sclerotherapy using a proprietary dispensing system to control foam characteristics and gas content for treating varicose veins.
Methods:
We reviewed in vitro, Phase I, Phase II and limited Phase III data for polidocanol microfoam with a focus on controlled foam formulation in therapy.
Results/conclusions:
Clinical trials of controlled dispensing of polidocanol microfoam provide evidence of effective treatment of chronic venous insufficiency with low toxicity, minimal risk and few complications.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Chemistry, Pharmaceutical / instrumentation
-
Chemistry, Pharmaceutical / methods
-
Clinical Trials as Topic
-
Dosage Forms
-
Embolism, Air / blood
-
Humans
-
Injections, Intravenous
-
Polidocanol
-
Polyethylene Glycols / administration & dosage
-
Polyethylene Glycols / adverse effects
-
Polyethylene Glycols / therapeutic use*
-
Sclerosing Solutions / administration & dosage
-
Sclerosing Solutions / adverse effects
-
Sclerosing Solutions / therapeutic use*
-
Sclerotherapy / adverse effects
-
Sclerotherapy / instrumentation
-
Sclerotherapy / methods*
-
Varicose Veins / therapy
-
Venous Insufficiency / complications
-
Venous Insufficiency / therapy
Substances
-
Dosage Forms
-
Sclerosing Solutions
-
Polidocanol
-
Polyethylene Glycols